Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 35

1.

Small Cell Lung Cancer Therapeutic Responses Through Fractal Measurements: From Radiology to Mitochondrial Biology.

Mambetsariev I, Mirzapoiazova T, Lennon F, Jolly MK, Li H, Nasser MW, Vora L, Kulkarni P, Batra SK, Salgia R.

J Clin Med. 2019 Jul 16;8(7). pii: E1038. doi: 10.3390/jcm8071038.

2.

Inhibiting crosstalk between MET signaling and mitochondrial dynamics and morphology: a novel therapeutic approach for lung cancer and mesothelioma.

Wang J, Mirzapoiazova T, Carol Tan YH, Pang KM, Pozhitkov A, Wang Y, Wang Y, Mambetsariev B, Wang E, Nasser MW, Batra SK, Raz D, Reckamp K, Kulkarni P, Zheng Y, Salgia R.

Cancer Biol Ther. 2018;19(11):1023-1032. doi: 10.1080/15384047.2018.1472193. Epub 2018 Oct 12.

3.

Down-regulation of micro-RNA-1 (miR-1) in lung cancer. Suppression of tumorigenic property of lung cancer cells and their sensitization to doxorubicin-induced apoptosis by miR-1.

Nasser MW, Datta J, Nuovo G, Kutay H, Motiwala T, Majumder S, Wang B, Suster S, Jacob ST, Ghoshal K.

J Biol Chem. 2018 Aug 17;293(33):12945. doi: 10.1074/jbc.W118.004967. No abstract available.

4.

Fibroblast-derived CXCL12 promotes breast cancer metastasis by facilitating tumor cell intravasation.

Ahirwar DK, Nasser MW, Ouseph MM, Elbaz M, CuitiƱo MC, Kladney RD, Varikuti S, Kaul K, Satoskar AR, Ramaswamy B, Zhang X, Ostrowski MC, Leone G, Ganju RK.

Oncogene. 2018 Aug;37(32):4428-4442. doi: 10.1038/s41388-018-0263-7. Epub 2018 May 3.

PMID:
29720724
5.

Focal adhesion kinase a potential therapeutic target for pancreatic cancer and malignant pleural mesothelioma.

Kanteti R, Mirzapoiazova T, Riehm JJ, Dhanasingh I, Mambetsariev B, Wang J, Kulkarni P, Kaushik G, Seshacharyulu P, Ponnusamy MP, Kindler HL, Nasser MW, Batra SK, Salgia R.

Cancer Biol Ther. 2018 Apr 3;19(4):316-327. doi: 10.1080/15384047.2017.1416937. Epub 2018 Feb 22.

6.

STAT1 gene deficient mice develop accelerated breast cancer growth and metastasis which is reduced by IL-17 blockade.

Varikuti S, Oghumu S, Elbaz M, Volpedo G, Ahirwar DK, Alarcon PC, Sperling RH, Moretti E, Pioso MS, Kimble J, Nasser MW, Ganju RK, Terrazas C, Satoskar AR.

Oncoimmunology. 2017 Aug 14;6(11):e1361088. doi: 10.1080/2162402X.2017.1361088. eCollection 2017.

7.

TRPV2 is a novel biomarker and therapeutic target in triple negative breast cancer.

Elbaz M, Ahirwar D, Xiaoli Z, Zhou X, Lustberg M, Nasser MW, Shilo K, Ganju RK.

Oncotarget. 2016 May 27;9(71):33459-33470. doi: 10.18632/oncotarget.9663. eCollection 2018 Sep 11.

8.

Novel role of cannabinoid receptor 2 in inhibiting EGF/EGFR and IGF-I/IGF-IR pathways in breast cancer.

Elbaz M, Ahirwar D, Ravi J, Nasser MW, Ganju RK.

Oncotarget. 2017 May 2;8(18):29668-29678. doi: 10.18632/oncotarget.9408.

9.

RAGE: A novel target for breast cancer growth and metastasis.

Nasser MW, Ahirwar DK, Ganju RK.

Oncoscience. 2016 Mar 3;3(2):52-3. eCollection 2016. No abstract available.

10.

Endothelial Robo4 suppresses breast cancer growth and metastasis through regulation of tumor angiogenesis.

Zhao H, Ahirwar DK, Oghumu S, Wilkie T, Powell CA, Nasser MW, Satoskar AR, Li DY, Ganju RK.

Mol Oncol. 2016 Feb;10(2):272-81. doi: 10.1016/j.molonc.2015.10.007. Epub 2015 Oct 28.

11.

Cannabinoid receptor-2 agonist inhibits macrophage induced EMT in non-small cell lung cancer by downregulation of EGFR pathway.

Ravi J, Elbaz M, Wani NA, Nasser MW, Ganju RK.

Mol Carcinog. 2016 Dec;55(12):2063-2076. doi: 10.1002/mc.22451. Epub 2016 Jan 6.

PMID:
26741322
12.

Erratum to: miR-29b defines the pro-/anti-proliferative effects of S100A7 in breast cancer.

Zhao H, Wilkie T, Deol Y, Sneh A, Ganju A, Basree M, Nasser MW, Ganju RK.

Mol Cancer. 2015 Nov 16;14(1):195. doi: 10.1186/s12943-015-0451-9. No abstract available.

13.

Non-contact method for directing electrotaxis.

Ahirwar DK, Nasser MW, Jones TH, Sequin EK, West JD, Henthorne TL, Javor J, Kaushik AM, Ganju RK, Subramaniam VV.

Sci Rep. 2015 Jun 9;5:11005. doi: 10.1038/srep11005.

14.

Conditioning solid tumor microenvironment through inflammatory chemokines and S100 family proteins.

Nasser MW, Elbaz M, Ahirwar DK, Ganju RK.

Cancer Lett. 2015 Aug 28;365(1):11-22. doi: 10.1016/j.canlet.2015.05.002. Epub 2015 May 8. Review.

PMID:
25963887
15.

Fatty acid binding protein 5 promotes metastatic potential of triple negative breast cancer cells through enhancing epidermal growth factor receptor stability.

Powell CA, Nasser MW, Zhao H, Wochna JC, Zhang X, Shapiro C, Shilo K, Ganju RK.

Oncotarget. 2015 Mar 20;6(8):6373-85.

16.

Modulation of the tumor microenvironment and inhibition of EGF/EGFR pathway: novel anti-tumor mechanisms of Cannabidiol in breast cancer.

Elbaz M, Nasser MW, Ravi J, Wani NA, Ahirwar DK, Zhao H, Oghumu S, Satoskar AR, Shilo K, Carson WE 3rd, Ganju RK.

Mol Oncol. 2015 Apr;9(4):906-19. doi: 10.1016/j.molonc.2014.12.010. Epub 2015 Jan 19.

17.

miR-29b defines the pro-/anti-proliferative effects of S100A7 in breast cancer.

Zhao H, Wilkie T, Deol Y, Sneh A, Ganju A, Basree M, Nasser MW, Ganju RK.

Mol Cancer. 2015 Jan 27;14:11. doi: 10.1186/s12943-014-0275-z. Erratum in: Mol Cancer. 2015;14(1):195.

18.

RAGE mediates S100A7-induced breast cancer growth and metastasis by modulating the tumor microenvironment.

Nasser MW, Wani NA, Ahirwar DK, Powell CA, Ravi J, Elbaz M, Zhao H, Padilla L, Zhang X, Shilo K, Ostrowski M, Shapiro C, Carson WE 3rd, Ganju RK.

Cancer Res. 2015 Mar 15;75(6):974-85. doi: 10.1158/0008-5472.CAN-14-2161. Epub 2015 Jan 8.

19.

C-X-C motif chemokine 12/C-X-C chemokine receptor type 7 signaling regulates breast cancer growth and metastasis by modulating the tumor microenvironment.

Wani N, Nasser MW, Ahirwar DK, Zhao H, Miao Z, Shilo K, Ganju RK.

Breast Cancer Res. 2014 May 29;16(3):R54. doi: 10.1186/bcr3665.

20.

Supplemental Content

Loading ...
Support Center